**Sensei Biotherapeutics to Present Clinical Data at Upcoming
Oncology Medical Conferences**

*Data to highlight SNS-301, a first-in-class cancer immunotherapy targeting ASPH, a novel
tumor-specific antigen*

GAITHERSBURG, MD, October 9, 2018 – Sensei Biotherapeutics, Inc., a clinical-stage
biopharmaceutical company discovering and developing precision immuno-oncology therapies, today
announced that it will present clinical data for SNS-301, its first-in-class cancer immunotherapy
candidate, at two upcoming oncology medical meetings.

The company will present results from its Phase 1 study of SNS-301 in antigen-positive patients targeting
human aspartate β-hydroxylase (ASPH), a novel tumor-specific embryonic antigen, at a Poster Discussion
session at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place October 19-
23 in Munich. Sensei will also present additional data on the antigen-specific immune responses achieved
using SNS-301 in this clinical study, at the 33rd Annual Meeting of the Society for Immunotherapy of
Cancer (SITC), taking place November 9-11 in Washington DC.

Details of the presentations on SNS-301 are as follows:

European Society for Medical Oncology (ESMO) 2018 Congress

Title:	Final Results from a Phase 1 Clinical Trial Evaluating the Safety, Immunogenicity, and Anti-Tumor Activity of SNS-301 in Men with Biochemically Relapsed Prostate Cancer
Session Type:	Poster Discussion session – Development therapeutics / investigational immunotherapy
Date & Time:	October 20, 2018, 3:00 - 4:15 p.m. CET
Location:	Hall B3 – Room 22
Presentation #:	416PD
Poster Display:	In designated Poster Discussion area, displayed for the duration of the Congress

Society for Immunotherapy of Cancer (SITC) Annual Meeting

Title:	Characterization of antigen specific immune responses from a first-in-human study evaluating the anti-ASPH cancer vaccine SNS-301 in biochemically relapsed prostate cancer patients
Session Type:	Poster session
Date & Time:	Friday, November 9, 2018, from 8 a.m. – 8 p.m. ET Saturday, November 10, 2018, from 8 a.m. – 8:30 p.m. ET
Location:	Hall E
Poster #:	P167

About SNS-301

SNS-301 is a first-in-class cancer immunotherapy targeting human aspartate β-hydroxylase (ASPH), a cell surface enzyme that is normally expressed during fetal development. Following fetal development, the protein is no longer expressed. Expression of ASPH is uniquely upregulated in more than 20 different types of cancer and is related to cancer cell growth, cell motility and invasiveness. ASPH expression levels in various tumors are inversely correlated with disease prognosis. Through enhanced antigen presentation and other engineered immunotherapeutic features, SNS-301 is designed to overcome self-tolerance and induce robust and durable ASPH-specific humoral and cellular immune responses that are specific to ASPH. SNS-301 is paired with a companion diagnostic to select antigen-positive patients and is delivered through intradermal injection to facilitate administration and aid in generating robust immune response.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company discovering and developing precision immuno-oncology therapies to transform the cancer treatment landscape. The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine for the treatment of head and neck cancer and myelodysplastic syndrome, as well as other solid tumors and hematological cancers. SNS-301 targets a novel embryonic antigen and has successfully completed a Phase 1 clinical study. Sensei's precision medicine approach in immuno-oncology includes the use companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit www.senseibio.com.

Contact:
Kathryn Morris
The Yates Network
914-204-6412
kathryn@theyatesnetwork.com